{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:46:00Z","timestamp":1787010360554,"version":"build-2736575974"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/spc.0000000000000090","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T08:41:36Z","timestamp":1412671296000},"page":"407-413","source":"Crossref","is-referenced-by-count":57,"title":["Role of osteocytes in multiple myeloma bone disease"],"prefix":"10.1097","volume":"8","author":[{"given":"Jesus","family":"Delgado-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20211004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease.","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"R2-18-20211004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease.","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"R3-18-20211004","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/leu.2013.258","article-title":"Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.","volume":"28","author":"Greenberg","year":"2014","journal-title":"Leukemia"},{"key":"R5-18-20211004","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1359\/jbmr.2001.16.9.1575","article-title":"Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers.","volume":"16","author":"Hauge","year":"2001","journal-title":"J Bone Miner Res"},{"key":"R6-18-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.060910","article-title":"Remodeling and vascular spaces in bone.","volume":"22","author":"Eriksen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R7-18-20211004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone.","volume":"174","author":"Andersen","year":"2009","journal-title":"Am J Pathol"},{"key":"R8-18-20211004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","article-title":"Osteocyte-driven bone remodeling.","volume":"94","author":"Bellido","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"R9-18-20211004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte.","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R10-18-20211004","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"key":"R11-18-20211004","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression.","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"key":"R12-18-20211004","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation.","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"key":"R13-18-20211004","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","article-title":"Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction.","volume":"5","author":"Tatsumi","year":"2007","journal-title":"Cell Metab"},{"key":"R14-18-20211004","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.060107","article-title":"Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.","volume":"21","author":"Aguirre","year":"2006","journal-title":"J Bone Min Res"},{"key":"R15-18-20211004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1138\/20070272","article-title":"Osteocyte apoptosis induces bone resorption and impairs the skeletal response to weightlessness.","volume":"4","author":"Bellido","year":"2007","journal-title":"BoneKEy-Osteovision"},{"key":"R16-18-20211004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00774-009-0154-7","article-title":"Targeting the bone microenvironment in multiple myeloma.","volume":"28","author":"Roodman","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"R17-18-20211004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2009.07980.x","article-title":"Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.","volume":"148","author":"Andersen","year":"2010","journal-title":"Br J Haematol"},{"key":"R18-18-20211004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"R19-18-20211004","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","article-title":"Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo.","volume":"90","author":"Bataille","year":"1995","journal-title":"Br J Haematol"},{"key":"R20-18-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease.","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br J Haematol"},{"key":"R21-18-20211004","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"R22-18-20211004","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood-2002-08-2641","article-title":"AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.","volume":"101","author":"Choi","year":"2003","journal-title":"Blood"},{"key":"R23-18-20211004","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2013.385","article-title":"Bone marrow monocytemacrophage derived activin a mediates the osteoclastogenic effect of IL-3 in multiple myeloma.","volume":"28","author":"Silbermann","year":"2014","journal-title":"Leukemia"},{"key":"R24-18-20211004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.0105-2896.2005.00323.x","article-title":"The role of immune cells and inflammatory cytokines in Pagets disease and multiple myeloma.","volume":"208","author":"Ehrlich","year":"2005","journal-title":"Immunol Rev"},{"key":"R25-18-20211004","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"R26-18-20211004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand RANKL.","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp Hematol"},{"key":"R27-18-20211004","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11914-014-0194-3","article-title":"Apoptotic osteocytes and the control of targeted bone resorption.","volume":"12","author":"Plotkin","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"R28-18-20211004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1359\/jbmr.081210","article-title":"Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue.","volume":"24","author":"Cardoso","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R29-18-20211004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09243860500096248","article-title":"Microdamage and apoptosis.","volume":"42","author":"Noble","year":"2005","journal-title":"Eur J Morphol"},{"key":"R31-18-20211004","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bone.2012.01.025","article-title":"Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations.","volume":"50","author":"Kennedy","year":"2012","journal-title":"Bone"},{"key":"R32-18-20211004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jor.21229","article-title":"Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.","volume":"29","author":"Brennan","year":"2011","journal-title":"J Orthop Res"},{"key":"R33-18-20211004","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"key":"R34-18-20211004","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/jcb.23164","article-title":"Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro.","volume":"112","author":"Al-Dujaili","year":"2011","journal-title":"J Cell Biochem"},{"key":"R35-18-20211004","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jbmr.548","article-title":"Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation.","volume":"27","author":"Bivi","year":"2012","journal-title":"J Bone Min Res"},{"key":"R36-18-20211004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/path.2322","article-title":"Metastases and multiple myeloma generate distinct transcriptional footprints in osteocytes in vivo.","volume":"214","author":"Eisenberger","year":"2008","journal-title":"J Pathol"},{"key":"R37-18-20211004","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.","volume":"49","author":"Bellido","year":"2011","journal-title":"Bone"},{"key":"R38-18-20211004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"R39-18-20211004","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/345442a0","article-title":"The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene.","volume":"345","author":"Yoshida","year":"1990","journal-title":"Nature"},{"key":"R40-18-20211004","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bone.2012.08.121","article-title":"Osteocyte control of osteoclastogenesis.","volume":"54","author":"OBrien","year":"2013","journal-title":"Bone"},{"key":"R41-18-20211004","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCEosteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-18-20211004","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerinosteoprotegerin ligand system in the human bone marrow environment.","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"R43-18-20211004","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1158\/0008-5472.CAN-12-2280","article-title":"RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.","volume":"73","author":"Schmiedel","year":"2013","journal-title":"Cancer Res"},{"key":"R44-18-20211004","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma.","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"R46-18-20211004","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.","volume":"84","author":"Vij","year":"2009","journal-title":"Am J Hematol"},{"key":"R47-18-20211004","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"R48-18-20211004","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha4beta1-integrin enhances production of osteoclast-stimulating activity.","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"R49-18-20211004","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand RANKL in T lymphocytes: a potential role in multiple myeloma bone disease.","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"R50-18-20211004","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood.V122.21.3140.3140","article-title":"Direct cell-to-cell interactions between osteocytes and multiple myeloma MM cells upregulate Sost and downregulate OPG expression in osteocytes: evidence for osteocytic contributions to MM-induced bone disease.","volume":"122","author":"Delgado-Calle","year":"2013","journal-title":"Blood"},{"key":"R51-18-20211004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11914-014-0188-1","article-title":"Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.","volume":"12","author":"Weivoda","year":"2014","journal-title":"Curr Osteoporos Rep"},{"key":"R52-18-20211004","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.","volume":"199","author":"Van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"key":"R53-18-20211004","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","article-title":"Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.","volume":"35","author":"Sutherland","year":"2004","journal-title":"Bone"},{"key":"R54-18-20211004","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP56 and antagonizes canonical Wnt signaling.","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"R55-18-20211004","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1210\/jc.2003-030201","article-title":"Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.","volume":"88","author":"Wergedal","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R56-18-20211004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease.","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet"},{"key":"R58-18-20211004","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr Rev"},{"key":"R59-18-20211004","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction postbortezomib monotherapy.","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"R60-18-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients.","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"R61-18-20211004","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2014.02.010","article-title":"Bone marrow plasma macrophage inflammatory protein protein-1 alpha MIP-1 alpha and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.","volume":"38","author":"Wang","year":"2014","journal-title":"Leuk Res"},{"key":"R62-18-20211004","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion.","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J"},{"key":"R63-18-20211004","first-page":"266","article-title":"Osteogenic inhibition in multiple myeloma.","volume":"15","author":"Habibi","year":"2013","journal-title":"Cell J"},{"key":"R64-18-20211004","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1464-5491.2010.03048.x","article-title":"Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression.","volume":"27","author":"Mabilleau","year":"2010","journal-title":"Diabet Med"},{"key":"R65-18-20211004","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"}],"container-title":["Current Opinion in Supportive & Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201412000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T09:42:41Z","timestamp":1633513361000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201412000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000090","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}